C. V. Paya

Pretransplantation Assessment of the Risk of Lymphoproliferative Disorder

Randall C. Walker, W.F. Marshall, John G. Strickler et al. · Clinical Infectious Diseases · 1995 · 395 citations

Medicine, Immunology, Internal Medicine +17

Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF‐kappa B.

Betsy Frantz, E.C. Nordby, Gary D. Bren et al. · The EMBO Journal · 1994 · 332 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +6

Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes

Andrew D. Badley, J A McElhinny, Paul J. Leibson et al. · Journal of Virology · 1996 · 310 citations · Full text

Life Sciences, Cell Biology, Immunology +17

The characterization of the promoter of the gene encoding the p50 subunit of NF‐kappa B indicates that it participates in its own regulation.

Rosa Ten, C. V. Paya, Nicole Israël et al. · The EMBO Journal · 1992 · 249 citations · Full text

Life Sciences, Genetics, Molecular Biology +12

Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.

Randall C. Walker, C. V. Paya, W.F. Marshall et al. · PubMed · 1995 · 244 citations

Medicine, Immunology, Pathology +14